caa a22 4500 445887702 CHVBK 20180317145604.0 cr unu---uuuuu 170323e20110101xx s 000 0 eng 10.1007/s00535-010-0331-4 doi (NATIONALLICENCE)springer-10.1007/s00535-010-0331-4 Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy [Elektronische Daten] [Shigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami] Reactivation of hepatitis B virus (HBV) has been reported as a fatal complication following systemic chemotherapy or other immunosuppressive therapy. The risk of HBV reactivation differs according to both the patient's HBV infection status prior to systemic chemotherapy and the degree of immunosuppression due to chemotherapy. For establishing an optimal strategy for hepatitis prevention and treatment, it is necessary to understand the characteristics, the clinical course and the risk factors for HBV reactivation and to recognize the difference between hepatitis B surface antigen (HBsAg)-positive and -negative patients with HBV reactivation. Among the important viral risk factors, HBV-DNA level and HBV-related serum markers have been reported to be associated with HBV reactivation in addition to cccDNA, genotypes and gene mutations. Rituximab-plus-steroid combination chemotherapy has recently been identified as a host risk factor for HBV reactivation in hepatitis B core antibody (anti-HBc)-positive and/or hepatitis B surface antibody (anti-HBs) positive—but nonetheless HBsAg-negative—lymphoma patients. For these patients with resolved hepatitis B, preemptive therapy guided by serial HBV-DNA monitoring is a reasonable strategy to enable early diagnosis of HBV reactivation and initiation of antiviral therapy. In this review, we summarize the characteristics of HBV reactivation following rituximab-plus-steroid combination chemotherapy, mainly in HBsAg-negative lymphoma patients, and propose a strategy for managing HBV reactivation. Springer, 2010 Reactivation nationallicence HBV nationallicence Rituximab nationallicence Anti-HBc : Hepatitis B core antibody nationallicence Anti-HBs : Hepatitis B surface antibody nationallicence cccDNA : Covalently closed circular DNA nationallicence CHOP : Cyclophosphamide, doxorubicin, vincristine, prednisolone nationallicence HBsAg : Hepatitis B surface antigen nationallicence HBV : Hepatitis B virus nationallicence HSCT : Hematopoietic stem cell transplantation nationallicence R-CHOP : Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone nationallicence RTD-PCR : Real-time detection PCR nationallicence Kusumoto Shigeru Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, 467-8601, Mizuho-ku, Nagoya, Aichi, Japan aut Tanaka Yasuhito Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, 467-8601, Mizuho-ku, Nagoya, Japan aut Ueda Ryuzo Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, 467-8601, Mizuho-ku, Nagoya, Aichi, Japan aut Mizokami Masashi Research Center for Hepatitis and Immunology, International Medical Center of Japan Konodai Hospital, Ichikawa, Chiba, Japan aut Journal of Gastroenterology Springer Japan 46/1(2011-01-01), 9-16 0944-1174 46:1<9 2011 46 535 https://doi.org/10.1007/s00535-010-0331-4 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00535-010-0331-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kusumoto Shigeru Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, 467-8601, Mizuho-ku, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Tanaka Yasuhito Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, 467-8601, Mizuho-ku, Nagoya, Japan aut NATIONALLICENCE 700 1- Ueda Ryuzo Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, 467-8601, Mizuho-ku, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Mizokami Masashi Research Center for Hepatitis and Immunology, International Medical Center of Japan Konodai Hospital, Ichikawa, Chiba, Japan aut NATIONALLICENCE 773 0- Journal of Gastroenterology Springer Japan 46/1(2011-01-01), 9-16 0944-1174 46:1<9 2011 46 535 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer